Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease

Animesh Pardanani; Terra L. Reeder; Teresa K. Kimlinger; Jin Y. Baek; Chin Y. Li; Joseph H. Butterfield; Ayalew Tefferi

doi:10.1016/S0145-2126(02)00303-X

Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease

Animesh Pardanani, Terra L. Reeder, Teresa K. Kimlinger, Jin Y. Baek, Chin Y. Li, Joseph H. Butterfield, Ayalew Tefferi

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

We screened 115 patients with chronic myeloid disorders (CMD) for known flt-3 and c-kit mutations in both the juxtamembrane (JM) and the activation loop (AL) domains. None of the patients displayed flt-3 (JM or AL) or c-kit JM mutations. However, the c-kit AL (D816V) mutation was detected in 5 of 16 patients with systemic mast cell disease (SMCD) but in none of the remaining 99 patients with other CMD. In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia.

Original language	English (US)
Pages (from-to)	739-742
Number of pages	4
Journal	Leukemia Research
Volume	27
Issue number	8
DOIs	https://doi.org/10.1016/S0145-2126(02)00303-X
State	Published - Aug 1 2003

Keywords

Hematologic clonal malignancies
Leukemia
Receptor tyrosine kinase
Stem cells
c-kit mutation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S0145-2126(02)00303-X

Cite this

@article{830560e764ec40e29199a0a030eb5b09,

title = "Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease",

abstract = "We screened 115 patients with chronic myeloid disorders (CMD) for known flt-3 and c-kit mutations in both the juxtamembrane (JM) and the activation loop (AL) domains. None of the patients displayed flt-3 (JM or AL) or c-kit JM mutations. However, the c-kit AL (D816V) mutation was detected in 5 of 16 patients with systemic mast cell disease (SMCD) but in none of the remaining 99 patients with other CMD. In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia.",

keywords = "Hematologic clonal malignancies, Leukemia, Receptor tyrosine kinase, Stem cells, c-kit mutation",

author = "Animesh Pardanani and Reeder, {Terra L.} and Kimlinger, {Teresa K.} and Baek, {Jin Y.} and Li, {Chin Y.} and Butterfield, {Joseph H.} and Ayalew Tefferi",

year = "2003",

month = aug,

day = "1",

doi = "10.1016/S0145-2126(02)00303-X",

language = "English (US)",

volume = "27",

pages = "739--742",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease

AU - Pardanani, Animesh

AU - Reeder, Terra L.

AU - Kimlinger, Teresa K.

AU - Baek, Jin Y.

AU - Li, Chin Y.

AU - Butterfield, Joseph H.

AU - Tefferi, Ayalew

PY - 2003/8/1

Y1 - 2003/8/1

N2 - We screened 115 patients with chronic myeloid disorders (CMD) for known flt-3 and c-kit mutations in both the juxtamembrane (JM) and the activation loop (AL) domains. None of the patients displayed flt-3 (JM or AL) or c-kit JM mutations. However, the c-kit AL (D816V) mutation was detected in 5 of 16 patients with systemic mast cell disease (SMCD) but in none of the remaining 99 patients with other CMD. In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia.

AB - We screened 115 patients with chronic myeloid disorders (CMD) for known flt-3 and c-kit mutations in both the juxtamembrane (JM) and the activation loop (AL) domains. None of the patients displayed flt-3 (JM or AL) or c-kit JM mutations. However, the c-kit AL (D816V) mutation was detected in 5 of 16 patients with systemic mast cell disease (SMCD) but in none of the remaining 99 patients with other CMD. In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia.

KW - Hematologic clonal malignancies

KW - Leukemia

KW - Receptor tyrosine kinase

KW - Stem cells

KW - c-kit mutation

UR - http://www.scopus.com/inward/record.url?scp=0038204191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038204191&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00303-X

DO - 10.1016/S0145-2126(02)00303-X

M3 - Article

C2 - 12801532

AN - SCOPUS:0038204191

SN - 0145-2126

VL - 27

SP - 739

EP - 742

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this